However, the biotech and healthcare industries lost a step Tuesday after the introduction of a bill to replace Obamacare and a morning tweet from President Trump that targeted drug price.
Many investors previously thought that risks in the biotech segment would and the focus on drug pricing was limited to Hillary Clinton’s bid to the White House, but the rising price of pharmaceuticals and specialty drugs saw renewed attention after Trump stated that “pricing for American people will come way down,” with many traders worried about the potential negative effects on big pharma and biotech companies’ bottom line.
Investors who are wary of the potential changes and the effects it will have on the healthcare sector can take steps to hedge against further risks through inverse ETF options. For example, the ProShares UltraShort Health Care (NYSEArca: RXD) follows the -2x or -200% daily performance of the broader healthcare sector and the Direxion Daily Healthcare Bear 3x Shares (NYSEArca: SICK) takes the -3x or -300% daily performance of healthcare stocks.
Additionally, the Direxion Daily Pharmaceutical & Medical Bear 2X Shares (NYSE: PILS) may act as a hedge on medical and pharmaceutical stocks .
The Direxion Daily S&P Biotech Bear 1X Shares (NYSEArca: LABS) takes the simple inverse exposure to the S&P Biotechnology Select Industry Index while more aggressive traders can look to the Direxion Daily S&P Biotech Bear Shares (NYSEArca: LABD), which takes the -3x or -300% daily performance of the biotech sector, the ProShares UltraPro Short NASDAQ Biotechnology (NasdaqGM: ZBIO), which also tracks the -3x or -300% daily performance of the Nasdaq Biotechnology Index, and the ProShares Ultrashort Nasdaq Biotechnology (NasdaqGM: BIS), which tracks the -2x or -200% daily performance of the biotech space.